Transfusion complications in thalassemia patients: A report from the Centers for Disease Control and Prevention (CME)

Transfusion

Volumn 54, Issue 4, 2014, Pages 972-981

  Vichinsky, Elliott ^{a,b,c,d,e,f,g,h}   Neumayr, Lynne ^{a,b,c,d,e,f,g,h}   Trimble, Sean ^{a,b,c,d,e,f,g,h}   Giardina, Patricia J ^{a,b,c,d,e,f,g,h}   Cohen, Alan R ^{a,b,c,d,e,f,g,h}   Coates, Thomas ^{a,b,c,d,e,f,g,h}   Boudreaux, Jeanne ^{a,b,c,d,e,f,g,h}   Neufeld, Ellis J ^{a,b,c,d,e,f,g,h}   Kenney, Kristy ^{a,b,c,d,e,f,g,h}   Grant, Althea ^{a,b,c,d,e,f,g,h}   Thompson, Alexis A ^{a,b,c,d,e,f,g,h}  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; ALPHA THALASSEMIA; ARTICLE; BLOOD SAFETY; BLOOD TRANSFUSION; DIABETES MELLITUS; ERYTHROCYTE TRANSFUSION; GROWTH HORMONE DEFICIENCY; HEMOSIDEROSIS; HUMAN; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON CHELATION; IRON OVERLOAD; THALASSEMIA; THALASSEMIA INTERMEDIA;

ADOLESCENT; ADULT; BLOOD SAFETY; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; THALASSEMIA; UNITED STATES; YOUNG ADULT;

EID: 84898633977     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12348     Document Type: Article

References (65)

1. Modell B, Darlison M,. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487. (Pubitemid 351821761)
2. Weatherall DJ,. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-4336.
3. Vichinsky EP, MacKlin EA, Waye JS, Lorey F, Olivieri NF,. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005; 116: e818-825. (Pubitemid 46056461)
4. Cheng CK, Lee CK, Lin CK,. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion 2012; 52: 2220-2224.
5. Chu C, Ho H, Lee H, Chan YS, Chang FJ, Wang CL, Lin M,. Anti-"Mi(a)" immunization is associated with HLA-DRB1*0901. Transfusion 2009; 49: 472-478.
6. El Danasoury AS, Eissa DG, Abdo RM, Elalfy MS,. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. Transfusion 2012; 52: 43-47.
7. Lee CK, Ma ES, Tang M, Lam CC, Lin CK, Chan LC,. Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy-a review of cases from 1997 to 2001. Transfus Med 2003; 13: 227-231. (Pubitemid 36950560)
8. Pahuja S, Pujani M, Gupta SK, Chandra J, Jain M,. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology 2010; 15: 174-177.
9. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP,. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000; 96: 3369-3373.
10. Sirchia G, Zanella A, Parravicini A, Morelati F, Rebulla P, Masera G,. Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion 1985; 25: 110-112. (Pubitemid 15076901)
11. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C,. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58: 50-55. (Pubitemid 20042996)
12. Thompson AA, Cunningham MJ, Singer ST, Neufeld EJ, Vichinsky E, Yamashita R, Giardina P, Kim HY, Trachtenberg F, Kwiatkowski JL,; Thalassemia Clinical Research Network Investigators. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol 2011; 153: 121-128.
13. Wang L, Liang D, Liu H, Chang FC, Wang CL, Chan YS, Lin M,. Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan. Transfus Med 2006; 16: 200-203. (Pubitemid 43847083)
14. American Association of Blood Banks. Infectious complications of blood transfusions. In:, Vengelen-Tyler V, editor. AABB technical manual. Bethesda (MD): American Association of Blood Banks; 2008. p. 601-630.
15. Centers for Disease Control and Prevention (CDC). The National Healthcare Safety Network (NHSN) manual. In: CDC, editor. NHSN biovigilance component protocol. Atlanta (GA): Division of Healthcare Quality Promotion. National Center for Emerging and Zoonotic Infectious Diseases (proposed). Centers for Disease Control and Prevention; 2010. p. 30.
16. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR,; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 2004; 104: 34-39. (Pubitemid 38879833)
17. Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E,; Multi-Center Study of Iron Overload Research Group. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255-265. (Pubitemid 46564319)
18. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP,. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364: 710-718.
19. Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E,. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007; 49: 329-332. (Pubitemid 47236225)
20. Cappellini MD, Motta I, Musallam KM, Taher AT,. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci 2010; 1202: 231-236.
21. Ansar MM, Kooloobandi A,. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat 2002; 9: 390-392.
22. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Negro F, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2: 61-80.
23. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H,; SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-282. (Pubitemid 44428107)
24. Vamvakas EC, Blajchman MA,. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-3417.
25. Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, Elmenshawy NM, Darwish AM,. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther 2012; 5: 54-59.
26. Omar N, Salama K, Adolf S, El-Saeed GS, Abdel Ghaffar N, Ezzat N,. Major risk of blood transfusion in hemolytic anemia patients. Blood Coagul Fibrinolysis 2011; 22: 280-284.
27. Gubernot DM, Nakhasi HL, Mied PA, Asher DM, Epstein JS, Kumar S,. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion 2009; 49: 2759-2771.
28. Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP,. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009; 48: 25-30.
29. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M,. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155: 509-519.
30. Leiby DA,. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev 2011; 24: 14-28.
31. Leiby DA,. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006; 90: 157-165.
32. Mali S, Kachur SP, Arguin PM,; Division of Parasitic Diseases and Malaria, Center for Global Health; Centers for Disease Control and Prevention (CDC). Malaria surveillance-United States, 2010. MMWR Surveill Summ 2012; 61: 1-17.
33. Tonnetti L, Eder AF, Dy B, Kennedy J, Pisciotto P, Benjamin RJ, Leiby DA,. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009; 49: 2557-2563.
34. FDA. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2007. Washington, DC: US Food and Drug Administration (FDA), 2008.
35. Herman JH, Ayache S, Olkowska D,. Autoimmunity in transfusion babesiosis: a spectrum of clinical presentations. J Clin Apher 2010; 25: 358-361.
36. Bloch EM, Herwaldt BL, Leiby DA, Shaieb A, Herron RM, Chervenak M, Reed W, Hunter R, Ryals R, Hagar W, Xayavong MV, Slemenda SB, Pieniazek NJ, Wilkins PP, Kjemtrup AM,. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012; 52: 1517-1522.
37. Luban NL, McBride E, Ford JC, Gupta S,. Transfusion medicine problems and solutions for the pediatric hematologist/oncologist. Pediatr Blood Cancer 2012; 58: 1106-1111.
38. Klein HG, Spahn DR, Carson JL,. Red blood cell transfusion in clinical practice. Lancet 2007; 370: 415-426. (Pubitemid 47176657)
39. Stainsby D, Jones H, Wells AW, Gibson B, Cohen H,; SHOT Steering Group. Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005. Br J Haematol 2008; 141: 73-79. (Pubitemid 351347538)
40. Domen RE, Hoeltge GA,. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127: 316-320. (Pubitemid 36378695)
41. Hendrickson JE, Hillyer CD,. Noninfectious serious hazards of transfusion. Anesth Analg 2009; 108: 759-769.
42. Shimada E, Tadokoro K, Watanabe Y, Ikeda K, Niihara H, Maeda I, Isa K, Moriya S, Ashida T, Mitsunaga S, Nakajima K, Juji T,. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42: 766-773.
43. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS,. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990; 76: 1431-1437. (Pubitemid 20342762)
44. Bao W, Yu J, Heck S, Yazdanbakhsh K,. Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009; 113: 5624-5627.
45. Bao W, Zhong H, Li X, Lee MT, Schwartz J, Sheth S, Yazdanbakhsh K,. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am J Hematol 2011; 86: 1001-1006.
46. Hall AM, Cairns LS, Altmann DM, Barker RN, Urbaniak SJ,. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood 2005; 105: 2175-2179. (Pubitemid 40731810)
47. Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC,. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood 2007; 110: 2736-2743. (Pubitemid 47523199)
48. Hoppe C, Klitz W, Vichinsky E, Styles L,. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol 2009; 84: 462-464.
49. McPherson ME, Anderson AR, Castillejo MI, Hillyer CD, Bray RA, Gebel HM, Josephson CD,. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr Blood Cancer 2010; 54: 552-558.
50. Tatari-Calderone Z, Minniti CP, Kratovil T, Stojakovic M, Vollmer A, Barjaktarevic I, Zhang E, Hoang A, Luban NL, Vukmanovic S,. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol 2009; 47: 64-70.
51. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F,. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012; 120: 528-537.
52. Yu J, Heck S, Yazdanbakhsh K,. Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. Am J Hematol 2007; 82: 691-696. (Pubitemid 47221648)
53. Lasalle-Williams M, Nuss R, Le T, Cole L, Hassell K, Murphy JR, Ambruso DR,. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-1739.
54. Wilkinson K, Harris S, Gaur P, Haile A, Armour R, Teramura G, Delaney M,. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion 2011; 52: 381-388.
55. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, Siritanaratkul N, Fucharoen S,. Activated platelet-derived microparticles in thalassaemia. Br J Haematol 2007; 136: 462-471. (Pubitemid 46046305)
56. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J,. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142: 126-135. (Pubitemid 351783151)
57. Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT,. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44: 67-72. (Pubitemid 38177138)
58. Spinella PC, Dressler A, Tucci M, Carroll CL, Rosen RS, Hume H, Sloan SR, Lacroix J,; Pediatric Acute Lung Injury and Sepsis Investigators Network. Survey of transfusion policies at US and Canadian children's hospitals in 2008 and 2009. Transfusion 2010; 50: 2328-2335.
59. King KE, Shirey RS,. Transfusion management of patients with sickle cell disease: the continuing dilemma. Transfusion 2010; 50: 2-4.
60. Osby M, Shulman IA,. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129: 190-193. (Pubitemid 40204796)
61. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ,; Stroke Prevention Trial in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092. (Pubitemid 32848083)
62. Anstee DJ,. Red cell genotyping and the future of pretransfusion testing. Blood 2009; 114: 248-256.
63. King KE, Ness PM,. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion 2011; 51: 916-920.
64. Serious Hazards of Transfusion-United Kingdom (SHOT-UK). Serious hazards of transfusion for children. 2011 [cited 2012 Jul 31]: http://www.shotuk.org/wp- content/uploads/2010/03/SHOT-for-Children.pdf
65. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webb D,. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011; 152: 35-51.